Alternatively spliced tissue factor promotes breast cancer growth in a [Beta]1 integrin-dependent manner

• Published in: Proceedings of the National Academy of Sciences - PNAS 2013-07, Vol.110 (28), p.11517
• Main Authors: Kocatürk, Begüm, Van den Berg, Yascha W, Tieken, Chris, Mieog, J Sven D, de Kruijf, Esther M, Engels, Charla C, vander Ent, Martijn A, Kuppen, Peter J, Van de Velde, Cornelis J, Ruf, Wolfram, Reitsma, Pieter H, Osanto, Susanne, Liefers, Gerrit-Jan, Bogdanov, Vladimir Y, Versteeg, Henri H
• Format: Article
• Language: English
• Subjects: Binding sites; Breast cancer; Cancer therapies; Clinical outcomes; Coagulation; Gene expression; Tumors
• ISSN: 0027-8424; 1091-6490

Full-length tissue factor (flTF), the coagulation initiator, is overexpressed in breast cancer (BrCa), but associations between flTF expression and clinical outcome remain controversial. It is currently not known whether the soluble alternatively spliced TF form (asTF) is expressed in BrCa or impacts BrCa progression. We are unique in reporting that asTF, but not flTF, strongly associates with both tumor size and grade, and induces BrCa cell proliferation by binding to β1 integrins. asTF promotes oncogenic gene expression, anchorage-independent growth, and strongly up-regulates tumor expansion in a luminal BrCa model. In basal BrCa cells that constitutively express both TF isoforms, asTF blockade reduces tumor growth and proliferation in vivo. We propose that asTF plays a major role in BrCa progression acting as an autocrine factor that promotes tumor progression. Targeting asTF may comprise a previously unexplored therapeutic strategy in BrCa that stems tumor growth, yet does not impair normal hemostasis. [PUBLICATION ABSTRACT]